Want to see GB:VAL full AI Analyst Report?
Top Page
ValiRx plc
(LSE:VAL)
Select Model
Select Model
Rating:42Neutral
Price Target:
0.13 p
▼(-16.25% Downside)
Action:Reiterated
Date:06/28/26
The score is primarily constrained by weak financial performance—tiny revenue, sustained losses, and ongoing cash burn that is eroding equity—despite low debt. Technicals also detract, with the stock trading below major moving averages and negative MACD, indicating a strong downtrend. Valuation metrics provide limited support due to negative earnings and no dividend yield data.
Positive Factors
Focused therapeutic pipeline
Concentration on oncology and women’s health gives ValiRx a defined therapeutic focus for advancing its pipeline. If candidates progress successfully, this model can create value through development partnerships without requiring the company to commercialize a broad product portfolio itself.
Negative Factors
Declining, minimal revenue
Revenue remains too small to support the operating cost base and declined materially year over year. This indicates that ValiRx has not yet established a dependable commercial income stream, leaving financial performance heavily dependent on future licensing or partnering outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused therapeutic pipeline
Concentration on oncology and women’s health gives ValiRx a defined therapeutic focus for advancing its pipeline. If candidates progress successfully, this model can create value through development partnerships without requiring the company to commercialize a broad product portfolio itself.
Read all positive factors
ValiRx plc (VAL) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.85M
Dividend YieldN/A
Average Volume (3M)8.28M
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth-36.97%
EPS Growth62.76%
CountryUK
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,320,301,000
10 Day Avg. Volume4,422,273
30 Day Avg. Volume8,275,598
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)44.16
P/FCF Ratio-0.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ValiRx plc Business Overview & Revenue Model
Company Description
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to trea...
How the Company Makes Money
ValiRx plc’s primary way of making money is through the out-licensing and partnering of its drug candidates and associated intellectual property rather than selling finished pharmaceutical products directly. Revenues, when generated, are typically...
ValiRx plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.37K | 49.77K | 9.60K | 0.00 | 0.00 |
| Gross Profit | -6.25K | -217.22K | -246.04K | -224.27K | -228.79K |
| EBITDA | -2.18M | -1.86M | -2.04M | -2.37M | -1.45M |
| Net Income | -2.23M | -1.92M | -2.04M | -2.41M | -1.55M |
Balance Sheet | |||||
| Total Assets | 2.63M | 4.26M | 3.13M | 3.98M | 3.52M |
| Cash, Cash Equivalents and Short-Term Investments | 791.61K | 1.56M | 174.68K | 1.14M | 593.67K |
| Total Debt | 1.40K | 11.86K | 22.07K | 37.71K | 58.72K |
| Total Liabilities | 235.10K | 346.41K | 226.51K | 149.65K | 109.56K |
| Stockholders Equity | 2.86M | 4.32M | 3.22M | 4.05M | 3.60M |
Cash Flow | |||||
| Free Cash Flow | -1.52M | -1.62M | -2.08M | -1.71M | -1.26M |
| Operating Cash Flow | -1.51M | -1.58M | -1.77M | -1.71M | -1.26M |
| Investing Cash Flow | -13.58K | -38.16K | -306.18K | 0.00 | 0.00 |
| Financing Cash Flow | 759.35K | 3.00M | 1.12M | 2.26M | 7.34K |
ValiRx plc Technical Analysis
Negative
0.16
Price Trends
0.16
Negative
0.19
Negative
0.26
Negative
Market Momentum
>-0.01
Positive
19.19
Positive
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.16 is above the 20-day moving average (MA) of 0.16, above the 50-day MA of 0.16, and below the 200-day MA of 0.26, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 19.19 is Positive, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.
ValiRx plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £115.89M | -18.04 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £3.98M | -1.68 | -37.30% | ― | ― | 85.56% | |
47 Neutral | £46.70M | -9.20 | -284.01% | ― | ― | -105.65% | |
45 Neutral | £35.36M | -2.35 | -2807.75% | ― | ― | -28.29% | |
42 Neutral | £1.85M | -0.34 | -70.79% | ― | -36.97% | 62.76% | |
42 Neutral | £22.46M | -9.73 | -353.21% | 17.86% | ― | 36.67% |
* Healthcare Sector Average
GB:VAL
ValiRx plc
0.14
-0.61
-81.33%
GB:TCF
Evgen Pharma
0.19
-0.05
-22.92%
GB:IMM
ImmuPharma
3.60
-4.46
-55.33%
GB:SAR
Sareum Holdings
33.50
11.50
52.27%
GB:SCLP
Scancell Holdings
9.56
0.86
9.89%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
520.00
-374.00
-41.83%
ValiRx plc Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
ValiRx bolsters Cytolytix cancer IP with new European patent and delivery platform filing
Positive
Aug 10, 2026
ValiRx plc has strengthened the intellectual property position of its majority-owned subsidiary Cytolytix, with the European Patent Office indicating its intention to grant a second European patent covering polyleucine-based anti-cancer peptides l...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
ValiRx AGM Backs Strategy as Board Changes and Large Warrant Issue Follow
Positive
Jul 17, 2026
ValiRx plc announced that all resolutions were approved at its Annual General Meeting, reinforcing shareholder support for the current strategy in oncology and women’s health. The company also confirmed the departure of non-executive directo...
Business Operations and StrategyFinancial Disclosures
ValiRx tightens focus and cuts costs as auditors flag going-concern risk
Negative
Jun 22, 2026
ValiRx reported audited results for 2025 showing it has completed a strategic review, sharpened its focus on three core priorities, and reoriented its Inaphaea BioLabs unit to primarily support the company’s own pipeline while selectively pu...
Business Operations and Strategy
ValiRx Ends Dundee Evaluation After Cancer Asset Fails Licensing Criteria
Negative
Jun 22, 2026
ValiRx plc has ended its evaluation collaboration with the University of Dundee’s Drug Discovery Unit and Queen Mary University of London after the cancer-focused project failed to meet the company’s strict criteria for in-licensing. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.